Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, IRADIMED CORPORATION reported revenue of $84M, up 14.4% year over year. Operating margin was 31.2% and net margin 26.8%, on a free-cash-flow margin of 20.5% with capital expenditure at 9.3% of revenue. Every figure is computed directly from IRMD's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $84M | 31.2% | 26.8% |
| FY2024 | $73M | 30.0% | 26.3% |
| FY2023 | $66M | 30.6% | 26.2% |
| FY2022 | $53M | 29.3% | 24.1% |
| FY2021 | $42M | 23.5% | 22.3% |
How does IRMD compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.